Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes - PubMed (original) (raw)

. 1992 Jul;22(7):1795-802.

doi: 10.1002/eji.1830220719.

Affiliations

• PMID: 1623924
• DOI: 10.1002/eji.1830220719

Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes

M C Pandolfino et al. Eur J Immunol. 1992 Jul.

Abstract

To try to understand the functional significance of human melanoma-infiltrating lymphocytes (TIL), a clonal analysis of the specificity, T cell receptor (TcR) diversity and activation requirements of these lymphocytes isolated from four different tumors was carried out. Supporting the presence of in vivo primed tumor-specific T lymphocytes in these four tumors, a high frequency of the Cd8+ and CD4+ clones, obtained from the TIL cultured for a few days with recombinant interleukin (rIL)-2 and autologous tumor cells, exhibited a restricted lysis or proliferation in response to the autologous tumor cell line. In contrast, no tumor-specific clone was obtained from freshly extracted TIL, suggesting that the frequency of tumor-specific effectors remained low in these tumors. Only the CD8+ clones lysed the autologous tumor cells and their activity was major histocompatibility complex MHC class I restricted. Significant expansion of CD4+ and CD8+ tumor-specific clones required regular restimulation by autologous melanoma cells but also the addition of exogenous IL-2 and of Epstein-Barr virus-transformed B feeder cells. Five different tumor-specific clones, three CD8+ and two CD4+ clones were identified in a single tumor on the basis of their TcR gene configuration. Together, these data suggest that a spontaneous and diverse immune response, mediated by tumor-specific CD4+ as well as CD8+ T lymphocytes, arises in most MHC-bearing human melanomas but that antigen-MHC complex presentation by tumor cells does not, at least in vitro, allow a significant proliferation of these lymphocytes.

PubMed Disclaimer

Similar articles

• Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
  Guilloux Y, Viret C, Gervois N, Le Dréan E, Pandolfino MC, Diez E, Jotereau F. Guilloux Y, et al. Eur J Immunol. 1994 Sep;24(9):1966-73. doi: 10.1002/eji.1830240905. Eur J Immunol. 1994. PMID: 7522155
• Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
  Viret C, Davodeau F, Guilloux Y, Bignon JD, Semana G, Breathnach R, Jotereau F. Viret C, et al. Eur J Immunol. 1993 Jan;23(1):141-6. doi: 10.1002/eji.1830230123. Eur J Immunol. 1993. PMID: 8419164
• Human autologous tumor-specific T cells in malignant melanoma.
  Platsoucas CD. Platsoucas CD. Cancer Metastasis Rev. 1991 Jun;10(2):151-76. doi: 10.1007/BF00049412. Cancer Metastasis Rev. 1991. PMID: 1873855 Review.
• Lymphocyte-melanoma interaction: role of surface molecules.
  Becker JC, Bröcker EB. Becker JC, et al. Recent Results Cancer Res. 1995;139:205-14. doi: 10.1007/978-3-642-78771-3_15. Recent Results Cancer Res. 1995. PMID: 7597291 Review.

Cited by

• Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
  Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A. Tuyaerts S, et al. Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. doi: 10.1007/s00262-007-0334-z. Epub 2007 May 15. Cancer Immunol Immunother. 2007. PMID: 17503040 Free PMC article. Review.
• A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.
  Moreau-Aubry A, Le Guiner S, Labarrière N, Gesnel MC, Jotereau F, Breathnach R. Moreau-Aubry A, et al. J Exp Med. 2000 May 1;191(9):1617-24. doi: 10.1084/jem.191.9.1617. J Exp Med. 2000. PMID: 10790436 Free PMC article.
• Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides.
  Toujas L, Delcros JG, Diez E, Gervois N, Semana G, Corradin G, Jotereau F. Toujas L, et al. Immunology. 1997 Aug;91(4):635-42. doi: 10.1046/j.1365-2567.1997.00287.x. Immunology. 1997. PMID: 9378506 Free PMC article.
• Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
  Gervois N, Guilloux Y, Diez E, Jotereau F. Gervois N, et al. J Exp Med. 1996 May 1;183(5):2403-7. doi: 10.1084/jem.183.5.2403. J Exp Med. 1996. PMID: 8642353 Free PMC article.
• A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
  Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T. Guilloux Y, et al. J Exp Med. 1996 Mar 1;183(3):1173-83. doi: 10.1084/jem.183.3.1173. J Exp Med. 1996. PMID: 8642259 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program